Nova Eye Medical Limited
ELXMF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.28 | 0.06 | -0.02 | -0.00 |
| FCF Yield | -17.16% | -27.10% | -31.29% | -723.57% |
| EV / EBITDA | -5.29 | -4.66 | -1.91 | 0.59 |
| Quality | ||||
| ROIC | -20.49% | -36.34% | -43.11% | -17.88% |
| Gross Margin | 64.54% | 86.57% | 4.95% | -5.72% |
| Cash Conversion Ratio | 0.68 | 0.89 | 0.44 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.79% | 20.36% | 8.32% | 1.57% |
| Free Cash Flow Growth | 22.37% | -10.44% | 26.80% | 32.11% |
| Safety | ||||
| Net Debt / EBITDA | 0.30 | 0.47 | 0.62 | 0.77 |
| Interest Coverage | -60.86 | -128.11 | -219.43 | -102.91 |
| Efficiency | ||||
| Inventory Turnover | 3.69 | 0.73 | 4.25 | 4.00 |
| Cash Conversion Cycle | 67.23 | 147.42 | 36.23 | 85.06 |